Background: Somatostatin analogs previously considered as adjuvant therapy in acromegaly are increasingly used as a first-line therapy in selected cases.
Objective: To review the octreotide LAR pharmacological and clinical data, and discuss the impact of this agent on current treatment regimens.
Methods: We reviewed PubMed publications since the first use of octreotide LAR in acromegaly, and historical articles related to the discovery and development of this molecule. We chose, for efficacy and safety data, reviews, clinical and randomized controlled trials that included >or=10 patients.
Results/conclusion: Octreotide LAR controls acromegaly in approximately 50-60% of patients by inhibiting GH and IGF-I secretion, and by reducing tumor size. This drug is well tolerated in most patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/17425255.4.6.783 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiation exposure and protection advice after [Lu]Lu-DOTA-TATE therapy in China.
EJNMMI Res
November 2024
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Article Synopsis
- - The study examined radiation exposure in 30 patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with [Lu]Lu-DOTA-TATE in China, focusing on radiation safety for patients and healthcare workers.
- - Researchers measured external dose rates and radiation doses to nurses and surroundings during and after treatment, determining safe contact times for patients' family members and coworkers post-therapy.
- - The findings established guidelines for when patients can resume daily interactions with others and confirmed that radiation exposure to medical staff and the hospital environment remained below national safety limits.
Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.
J Nephrol
December 2024
Chair of Nephrology, Department of Public Health, Federico II University, Naples, Italy.
Key Clinical Message: Pancreatic neuroendocrine tumors (PNETs) are rare and often misdiagnosed due to their vague symptoms and tumor heterogeneity. Early detection using computed tomography (CT) is essential, particularly in regions without access to advanced diagnostic tools like immunohistochemistry and genetic testing.
Abstract: Neuroendocrine tumors (NETs) are rare tumors in adults and extremely rare in the pediatric population, as pancreatic NETs (pNETs) have an incidence rate of <0.
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Clin Transl Oncol
September 2024
Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Introduction: The somatostatin analogs (SSA) octreotide and lanreotide are a mainstay in the treatment of neuroendocrine tumors (NET). The two pivotal trials differed considerably in terms of patient characteristics and are not directly comparable. Further comparative data are lacking.
View Article and Find Full Text PDFReal-world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study.
J Neuroendocrinol
December 2024
Department of Pancreatic Hepatobiliary Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence-based data and remains controversial. This study aimed to validate whether long-acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk by clustering real-world data. A retrospective review of patients with nonmetastatic grade 2 PanNETs who underwent radical resection at six research centers between 2008 and 2020 was conducted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!